567 related articles for article (PubMed ID: 24528057)
61. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
62. Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.
Gulyas M; Fillinger J; Kaposi AD; Molnar M
J Clin Pathol; 2019 Aug; 72(8):529-535. PubMed ID: 31028099
[TBL] [Abstract][Full Text] [Related]
63. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions.
Romero S; Fernández C; Arriero JM; Espasa A; Candela A; Martín C; Sánchez-Payá J
Eur Respir J; 1996 Jan; 9(1):17-23. PubMed ID: 8834328
[TBL] [Abstract][Full Text] [Related]
64. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
[TBL] [Abstract][Full Text] [Related]
65. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
Huang WW; Tsao SM; Lai CL; Su CC; Tseng CE
Pathology; 2010 Apr; 42(3):224-8. PubMed ID: 20350214
[TBL] [Abstract][Full Text] [Related]
66. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
Sthaneshwar P; Yap SF; Jayaram G
Malays J Pathol; 2002 Jun; 24(1):53-8. PubMed ID: 16329556
[TBL] [Abstract][Full Text] [Related]
67. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.
Lee SH; Park MJ; Choi SI; Lee EJ; Lee SY; In KH
Medicine (Baltimore); 2017 Jan; 96(4):e5975. PubMed ID: 28121949
[TBL] [Abstract][Full Text] [Related]
68. Diagnosis of malignant pleural effusion with combinations of multiple tumor markers: A comparison study of five machine learning models.
Zhang Y; Wang J; Liang B; Wu H; Chen Y
Int J Biol Markers; 2023 Jun; 38(2):139-146. PubMed ID: 36847282
[TBL] [Abstract][Full Text] [Related]
69. Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis.
Zhang Y; Li X; Liu J; Hu X; Wan C; Zhang R; Shen Y
Ann Med; 2021 Dec; 53(1):558-566. PubMed ID: 33818231
[TBL] [Abstract][Full Text] [Related]
70. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
71. Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion.
Loncar R; Ostojic L; Tabakovic-Loncar V; Roguljić A
Tumori; 1995; 81(6):440-4. PubMed ID: 8804473
[TBL] [Abstract][Full Text] [Related]
72. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
73. A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.
Saraya T; Ohkuma K; Koide T; Goto H; Takizawa H; Light RW
Medicine (Baltimore); 2019 Mar; 98(13):e15003. PubMed ID: 30921217
[TBL] [Abstract][Full Text] [Related]
74. Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites.
Trapé J; Gurt G; Franquesa J; Montesinos J; Arnau A; Sala M; Sant F; Casado E; Ordeig JM; Bergos C; Vida F; Sort P; Isava Á; González M; Molina R
Anticancer Res; 2015 Oct; 35(10):5655-60. PubMed ID: 26408739
[TBL] [Abstract][Full Text] [Related]
75. Use of tumor markers in distinguishing lung adenocarcinoma-associated malignant pleural effusion from tuberculous pleural effusion.
Ai L; Wang W; Li J; Ye T; Li Y
Am J Med Sci; 2024 Apr; ():. PubMed ID: 38583522
[TBL] [Abstract][Full Text] [Related]
76. Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid.
Lellé RJ; Henkel E; Leinemann D; Goeschen K
Gynecol Obstet Invest; 1989; 27(3):137-42. PubMed ID: 2737547
[TBL] [Abstract][Full Text] [Related]
77. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in malignant pleural effusion in patients with lung cancer.
Xu CH; Hao KK; Yu LK; Zhang XW
Asia Pac J Clin Oncol; 2015 Mar; 11(1):28-33. PubMed ID: 24720371
[TBL] [Abstract][Full Text] [Related]
78. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
79. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
80. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
